Home >> About

News & Events

Gothenburg, Sweden – 17 April 2012: Cortendo today announced an update and further information for the discovery collaboration in the cortisol modulation area with the Moulder Center for Drug Discovery Research at Temple University. The goal of the collaboration is to discover next generation compounds for type 2 diabetes and metabolic syndrome as well as orphan drug diseases.

Rochester, NY April 9, 2012: A new program, jointly funded by the University of Rochester Medical Center (URMC) and the Moulder Center for Drug Discovery Research at Temple University, will help researchers identify and test chemical compounds that could be candidates for new drugs.

The $500,000 fund, called the Drug Discovery Pilot Award Program, represents the next stage in a complementary relationship that was formed between URMC and the Moulder Center last year.

PHILADELPHIA – (February 22, 2012) – The Wistar Institute and The Moulder Center for Drug Discovery Research at Temple University today announce their new partnership to accelerate the transition of biomedical research into new drug therapies for cancer and other diseases.

The American Association of Colleges of Pharmacy (AACP) today announced the recipients of the 2011-2012 New Investigator Awards (NIA). The Awards support new faculty research in multidisciplinary areas such as biological sciences, chemistry, pharmaceutical sciences, pharmacy practice, and social and administrative sciences. This year’s 18 Award recipients are investigating topics as diverse as medication self-management, treatment for cocaine addiction and withdrawal, and the impact of Medicare payment cuts on treatment choices and patient outcomes.

Compared to the recent rocky roads of other U.S. industries — such as the automotive industry—the field of prescription drugs might appear to be holding its own: The IMS Institute forHealthcare Informatics reported its total 2010 sales to be more than $307 billion.

What that number does not reveal is that big pharma suffers from an “innovation gap,” the amount of products—or rather, lack thereof— coming through the industry pipeline.  In 1996, the industry hit its peak, with 56 new drugs approved for consumer use by the U.S. Food and Drug Administration. Since then, new drug approvals have steadily declined to as few as 18 per year.

11/28/2011 - GVK Biosciences (GVK BIO), Asia’s leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.

As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders.

Philadelphia, PA (11/15/2011) - Dr Magid Abou-Gharbia will be bringing the insights from a distinguished career to a key panel discussion at Chemspec USA. We caught up with him at Temple University in Philadelphia

Like so many people in the US chemicals industry, Dr Magid Abou-Gharbia, director of the Moulder Center for Drug Discovery within the School of Pharmacy at Temple University in Philadelphia, knew Ben Jones during his time at the American Chemical Society (ACS). He frequently participated in ACS conferences, notably on one his favourite topics, the future of the 'chemical enterprise' as it relates to the pharmaceuticals industry.

Magid Abou-Gharbia has a message for pharmaceutical industry scientists wondering what is next for them in this age of severe R&D cuts: There is life after pharma.

TINTAGEL, England (October 18, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that the Moulder Center for Drug Discovery Research at Temple University’s School of Pharmacy has selected the company’s Maybridge screening libraries to identify compounds that might be useful in treating health problems as diverse as Alzheimer’s disease, cancer and drug dependency.

Philadelphia, PA (09/09/2011) The merger mania that has swept through the pharmaceutical industry over the past decade has left drug companies looking for help in the early-stage drug discovery and development part of their business. In Philadelphia and around the country, academic medical centers and medical schools are stepping up to fill that void. 

Pages

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140